Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Nanologica AB is an innovative biotechnology company focused on the research and development of advanced silica-based nanoparticle technologies. Specializing in the life sciences sector, this Swedish firm leverages its core competencies in the production of mesoporous silica for diverse applications. Its primary purpose is to enhance drug formulation and delivery, thus improving the bioavailability and therapeutic efficacy of pharmaceuticals. Nanologica's platform plays a vital role in drug development processes, affecting industries such as pharmaceuticals and biotechnology. Known for its proprietary methods, Nanologica facilitates the development of both small molecules and biopharmaceuticals, thereby enabling new opportunities in drug discovery and delivery solutions. Positioned within the healthcare technology landscape, Nanologica AB's advancements contribute significantly to the pharmaceutical supply chain, emphasizing its market significance through collaborations and partnerships with major industry players.
kr 0.04
kr 0.00 (-2.04%)
Live · 11:04 PM · Twelve Data
The business is unprofitable at the operating level (-233.74% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 45.3% YoY with margins expanding 95.9pp.
Negative free cash flow of -kr 41M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
kr 21M
▲ +45.3% YoY
Net Income (FY)
-kr 51M
▲ +21.9% YoY
Op. Margin
-233.74%
▲ +95.9pp YoY
ROIC
-46.12%
▲ +14.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-kr 41M
▲ +49.8% YoY
Op. Cash Flow (FY)
-kr 34M
▲ +58.6% YoY
Net Debt
kr 18M
Cash & Equiv.
kr 4M
3Y CAGR: +138.6%
Continue Research
Nanologica AB (NICA.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nanologica AB scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Nanologica AB scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -233.7% operating margin and a -46.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NICA.XSTO's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.